GSTA1 rs2817101: What Your Genotype Means
The rs2817101 variant is a genetic change located within the GSTA1 gene, which encodes an enzyme responsible for metabolizing various drugs and toxins. Research has identified this variant as a potential factor influencing how breast cancer patients respond to doxorubicin chemotherapy.
What each genotype means
Typical GSTA1 genotype
This genotype represents the most common form of the GSTA1 gene in many populations. Research into this variant's role in doxorubicin treatment outcomes is ongoing, and current evidence is not sufficient to guide specific clinical decisions. Please discuss your treatment plan and any concerns regarding medication response with your oncologist or pharmacist.
This is the most frequent genotype observed in many global populations, though exact frequencies vary significantly by ancestry.
Heterozygous GSTA1 genotype
You carry one copy of each allele for this variant. While some studies investigate the role of GSTA1 in breast cancer chemotherapy response, the clinical significance of this specific genotype remains uncertain and is not currently used to adjust standard doxorubicin dosing. Always consult with your healthcare provider regarding your specific chemotherapy regimen.
This genotype is found at varying frequencies across different ethnic groups, appearing in a significant portion of the population.
Variant GSTA1 genotype
You carry two copies of the variant allele. While this variant has been studied for potential associations with survival outcomes in breast cancer patients treated with doxorubicin, the evidence is considered moderate and not yet definitive for clinical practice. You should discuss your medication options and any potential for differential drug response with your clinical team.
This genotype is less common than the homozygous AA genotype in many populations, with prevalence rates that differ by ancestral background.
Understanding the rs2817101 Variant
The rs2817101 variant is a single nucleotide polymorphism (SNP) found within the GSTA1 gene. In genetics, a SNP represents a variation at a single position in the DNA sequence among individuals. This specific variant is located in a region that can influence the expression levels of the GSTA1 enzyme. Because GSTA1 is involved in the detoxification and metabolism of various compounds, including chemotherapeutic agents, researchers study this SNP to understand if it contributes to the variability seen in how patients process medications. It is important to note that while this variant is a subject of scientific interest, it is just one of many genetic factors that may influence drug response, and its presence does not determine a clinical outcome on its own.
The Role of the GSTA1 Gene
The GSTA1 gene provides instructions for making the Glutathione S-transferase Alpha 1 enzyme. This enzyme is primarily expressed in the liver, where it plays a critical role in the detoxification of endogenous and exogenous substances, including many common cancer drugs like doxorubicin, cyclophosphamide, and busulfan. By facilitating the conjugation of glutathione to these compounds, the enzyme helps neutralize them or prepare them for excretion from the body. Because GSTA1 is highly expressed in the liver and also present in breast tissue, it is considered a key candidate gene for influencing drug clearance and efficacy. Variations in this gene can lead to differences in enzyme activity, which may theoretically alter the concentration of drugs in a patient's system during treatment.
Research and Evidence Strength
Current research has identified rs2817101 as a potential drug response marker, specifically in the context of doxorubicin treatment for breast cancer. Studies have suggested that the variant may act as a cis-eQTL, meaning it is associated with different expression levels of the GSTA1 gene. While some findings indicate that these expression differences might correlate with treatment outcomes, the evidence remains moderate. It is essential to recognize that pharmacogenomic associations are complex; they are often influenced by multiple genes, environmental factors, and the specific characteristics of the tumor. Because the evidence is not definitive, this variant is not currently used as a standard clinical tool for prescribing decisions. Any questions regarding chemotherapy regimens or potential side effects should always be directed to a qualified oncologist or pharmacist who can evaluate the full clinical picture.
Population Frequency and Variability
The frequency of the rs2817101 variant is known to be variable across different global populations. Genetic studies have shown that the distribution of GSTA1 haplotypes—which include various SNPs—differs significantly between ancestral groups. For example, certain metabolic phenotypes associated with GSTA1 are more common in East and South Asian populations compared to European populations. These differences highlight the importance of considering ancestry in pharmacogenomic research, as a variant that is common in one group may be rare in another. Because of this variability, researchers emphasize the need for diverse study cohorts to fully understand the impact of GSTA1 variants. Understanding these population-level differences is a key step in the ongoing effort to develop more personalized approaches to medicine.
What This Information Means for You
If you have information about your rs2817101 genotype, it is important to view it as a piece of scientific data rather than a medical diagnosis. This variant is currently a subject of research, and its clinical utility is not yet established for routine patient care. You cannot use this information to predict how you will respond to a specific medication or to make decisions about your treatment plan. If you are undergoing treatment for breast cancer or any other condition, your healthcare team is the best resource for discussing your care. They can provide guidance based on established clinical guidelines, your medical history, and the specific details of your treatment. Always consult with your clinician or pharmacist before making any changes to your medication or if you have concerns about your treatment response.
How common is this variant?
The frequency of the rs2817101 variant is variable across different global populations, with significant differences in GSTA1 haplotype distributions observed between ancestral groups.
Frequently asked questions
Can I use my rs2817101 result to choose my chemotherapy?
No. This variant is currently a subject of research and is not used to guide clinical treatment decisions. You should always follow the treatment plan recommended by your oncologist.
Is rs2817101 a cause of breast cancer?
There is no evidence that rs2817101 causes breast cancer. It is studied primarily for its potential role in how the body processes certain chemotherapy drugs.
Where can I find more information about GSTA1?
You can search resources like MedlinePlus Genetics or the NCBI Gene database for general information about the function of the GSTA1 gene. For clinical questions, always speak with your doctor.
Why do different populations have different GSTA1 frequencies?
Genetic variation is a natural result of human evolution and migration. Different populations have developed unique patterns of genetic diversity over time, which is why researchers study many different groups.
Sources & further reading
Educational information only, last refreshed 10/16/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs2817101?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29